Gate Direct IPO Phase 3 Anthropic allocation announced, final allocation of 92,100 shares of ANT
According to the official announcement, the quota for the third phase of Gate IPO Access for the Anthropic (ANT) project has been officially confirmed. The total intended subscription amount for this phase reached 152 million USDT, with a final allocation of 92,100 shares of ANT. Based on the issuance price of 83 USDT per share, the total value of the allocated shares amounts to 7,644,300 USDT, corresponding to a subscription allocation ratio of approximately 5.03%. The platform will allocate stock quotas based on the proportion of individual user investment amounts to the total subscription amount, and the stock distribution is expected to be completed within 1 to 3 hours after the announcement is released, with details subject to the official announcement.
The final issuance price for this IPO is 83 USD per share, which is approximately 6.41% higher than the previous reference price range upper limit of 70-78 USD per share, in line with the price deviation range specified for this subscription phase. This subscription is intended and does not represent a final allocation.
In addition, Anthropic (ANT) is now listed on Gate stocks. After the listing, it will first go through the IPO Cross price discovery phase, followed by the opening of normal trading, with specific timing subject to the actual trading status of the platform. Currently, Gate stock trading services cover five major markets: US stocks, Hong Kong stocks, Korean stocks, Japanese stocks, and Taiwanese stocks, supporting trading of over 12,800 stocks and ETF assets globally, and connecting pre-IPO subscriptions with post-listing trading through Pre-IPOs and IPO Access services, expanding global stock investment channels.
ChainCatcher reminds readers to view blockchain rationally, enhance risk awareness, and be cautious of various virtual token issuances and speculations. All content on this site is solely market information or related party opinions, and does not constitute any form of investment advice. If you find sensitive information in the content, please click , and we will handle it promptly.






